Article(id=1330127200214429792, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330127189372153867, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2018.02.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1507651200000, receivedDateStr=2017-10-11, revisedDate=1512576000000, revisedDateStr=2017-12-07, acceptedDate=null, acceptedDateStr=null, onlineDate=1795056637098, onlineDateStr=2026-11-19, pubDate=1518192000000, pubDateStr=2018-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795056637098, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795056637098, creator=13701087609, updateTime=1795056637098, updator=13701087609, issue=Issue{id=1330127189372153867, tenantId=1146029695717560320, journalId=1319690329412173987, year='2018', volume='39', issue='2', pageStart='S9', pageEnd='144', issueExtLink='null', onlineDate='null', pubDate='1518192000000', pubDateStr='2018-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795056634514, creator='13701087609', updateTime=1795056680728, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330127383656510048, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330127189372153867, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330127383656510049, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330127189372153867, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=80, endPage=86, ext={EN=ArticleExt(id=1330127200394784865, articleId=1330127200214429792, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Progress of the diagnosis and treatment for IgA (immunoglobin A) nephropathy, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

IgA nephropathy is the most common primary glomerulonephritis. Renal biopsy remains the definitive diagnostic method of IgA nephropathy. Recently, the development of new diagnostic markers and therapeutic drugs provide some new ideas for the diagnosis and treatment of IgA nephropathy. There is still a lack of specific immunosuppressive therapy. This review describes the progress of IgA nephropathy diagnosis and its treatment.

, authors=Yi-ping RUAN, Fu-yuan HONG*, authorsList=Yi-ping RUAN, Fu-yuan HONG, authorCompany=null, correspAuthors=Fu-yuan HONG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330127200742912098, articleId=1330127200214429792, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=IgA肾病诊断和治疗进展, columnId=1330127190638833678, journalTitle=世界临床药物, columnName=医药专论·慢性肾脏病的诊疗专题, runingTitle=null, highlight=null, articleAbstract=

IgA肾病是一种常见的原发性肾小球肾炎,肾活检是诊断IgA肾病的金标准,近年来出现的一些新的诊断标志物和新型治疗药物为疾病的诊断和治疗提供了新思路。目前尚缺乏特异性免疫抑制治疗方案。本文综述IgA肾病的诊断和治疗新进展。

, authors=阮一平, 洪富源*, authorsList=阮一平, 洪富源, authorCompany=null, correspAuthors=洪富源, authorNote=

阮一平,主治医师,主要研究方向为原发性肾小球疾病。

, correspAuthorsNote=
洪富源,主任医师,硕士生导师,主要研究方向原发性肾小球疾病和肾脏病替代治疗。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=E+tAmPd9b4Cof1hOJonVZg==, magXml=M9oCA/FiOmbpzdmHfmBUhQ==, pdfUrl=null, pdf=i2UjYl4Qt5F+WB4vry/n7A==, pdfFileSize=966254, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=HkT1ok/c4XjVnMdKlioxCA==, mapNumber=null, fund=null)}, authors=[Author(id=1330127201028124775, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127201124593769, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, authorId=1330127201028124775, language=EN, stringName=Yi-ping RUAN, firstName=Yi-ping, middleName=null, lastName=RUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127202747789418, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, authorId=1330127201028124775, language=CN, stringName=阮一平, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001, bio={"content":"

阮一平,主治医师,主要研究方向为原发性肾小球疾病。

"}, bioImg=null, bioContent=

阮一平,主治医师,主要研究方向为原发性肾小球疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127200906489955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, xref=null, ext=[AuthorCompanyExt(id=1330127200919072868, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China), AuthorCompanyExt(id=1330127200935850085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001)])]), Author(id=1330127202852647020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330127202928144494, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, authorId=1330127202852647020, language=EN, stringName=Fu-yuan HONG, firstName=Fu-yuan, middleName=null, lastName=HONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127202991059055, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, authorId=1330127202852647020, language=CN, stringName=洪富源, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127200906489955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, xref=null, ext=[AuthorCompanyExt(id=1330127200919072868, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China), AuthorCompanyExt(id=1330127200935850085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001)])])], keywords=[Keyword(id=1330127203095916656, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, language=EN, orderNo=1, keyword=IgA nephropathy), Keyword(id=1330127203163025521, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, language=EN, orderNo=2, keyword=diagnosis), Keyword(id=1330127203238522994, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, language=EN, orderNo=3, keyword=treatment), Keyword(id=1330127203318214771, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, language=CN, orderNo=1, keyword=IgA肾病), Keyword(id=1330127203385323636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, language=CN, orderNo=2, keyword=诊断), Keyword(id=1330127203448238197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, language=CN, orderNo=3, keyword=治疗)], refs=[Reference(id=1330127203624398967, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheng J, Zhang W, Zhang X H, et al. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials[J]. Int J Clin Pract, 2009, 63(6): 880-888., articleTitle=null, refAbstract=null), Reference(id=1330127203699896440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification[J]. Kidney Int, 2009, 76(5): 534-545., articleTitle=null, refAbstract=null), Reference(id=1330127203767005305, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments[J]. Kidney Int, 2014, 86(4): 828-836., articleTitle=null, refAbstract=null), Reference(id=1330127203829919866, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels[J]. Kidney Int, 2007, 71(11): 1148-1154., articleTitle=null, refAbstract=null), Reference(id=1330127203909611643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Tam KY, Leung JC, Chan LY, et al. Macromolecular IgA1 taken from patients with familial IgA nephropathy or their asymptomatic relatives have higher reactivity to mesangial cells in vitro[J]. Kidney Int, 2009, 75(12): 1330-1339., articleTitle=null, refAbstract=null), Reference(id=1330127203997692028, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Kiryluk K, Moldoveanu Z, Sanders JT, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis[J]. Kidney Int, 2011, 80(1): 79-87., articleTitle=null, refAbstract=null), Reference(id=1330127204081578109, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1[J]. J Clin Invest, 2008, 118(2): 629-639., articleTitle=null, refAbstract=null), Reference(id=1330127204178047102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity[J]. J Clin Invest, 2009, 119(6): 1668-1677., articleTitle=null, refAbstract=null), Reference(id=1330127204240961663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Novak J, Tomana M, Matousovic K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells[J]. Kidney Int, 2005, 67(2): 504-513., articleTitle=null, refAbstract=null), Reference(id=1330127204341624960, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Stangou M, Alexopoulos E, Papagianni A, et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin a nephropathy[J]. Nephrology (Carlton), 2009, 14(6): 613-620., articleTitle=null, refAbstract=null), Reference(id=1330127204412928129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Szeto CC, Li PK. MicroRNAs in IgA nephropathy[J]. Nat Rev Nephrol, 2014, 10(5): 249-256., articleTitle=null, refAbstract=null), Reference(id=1330127204501008514, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Nishiyama A, Konishi Y, Ohashi N, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy[J]. Nephrol Dial Transplant, 2011, 26(1): 170-177., articleTitle=null, refAbstract=null), Reference(id=1330127204580700291, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang JJ, Jiang L, Liu G, et al. Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity[J]. Scand J Immunol, 2009, 69(5): 457-464., articleTitle=null, refAbstract=null), Reference(id=1330127204652003460, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Bazzi C, Rizza V, Raimondi S, et al. In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression[J]. Clin J Am Soc Nephrol, 2009, 4(5): 929-935., articleTitle=null, refAbstract=null), Reference(id=1330127204719112325, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Serino G, Sallustio F, Cox SN, et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy[J]. J Am Soc Nephrol, 2012, 23(5): 814-824., articleTitle=null, refAbstract=null), Reference(id=1330127204794609798, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Serino G, Pesce F, Sallustio F, et al. In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy[J]. Kidney Int, 2016, 89(3): 683-692., articleTitle=null, refAbstract=null), Reference(id=1330127204878495879, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Reid S, Cawthon PM, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy[J]. Cochrane Database Syst Rev, 2011, 16(3): CD003962., articleTitle=null, refAbstract=null), Reference(id=1330127204953993352, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Tang SC, Lin M, Tam S, et al. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study[J]. Nephrol Dial Transplant, 2012, 27(2): 613-618., articleTitle=null, refAbstract=null), Reference(id=1330127205071433865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Szeto CC, Kwan BC, Chow KM, et al. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy-a randomized cross-over study[J]. PLoS One, 2013, 8(5): e62736., articleTitle=null, refAbstract=null), Reference(id=1330127205151125642, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient[J]. Kidney Int, 2012, 82(8): 840-856., articleTitle=null, refAbstract=null), Reference(id=1330127205268566155, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=De Caterina R, Endres S, Kristensen SD, et al. n-3 fatty acids and renal diseases[J]. Am J Kidney Dis, 1994, 24(3): 397-415., articleTitle=null, refAbstract=null), Reference(id=1330127205335675020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Donadio JJ, Bergstralh EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group[J]. N Engl J Med, 1994, 331(18): 1194-1199., articleTitle=null, refAbstract=null), Reference(id=1330127205427949709, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Donadio JJ, Larson TS, Bergstralh EJ, et al. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy[J]. J Am Soc Nephrol, 2001, 12(4): 791-799., articleTitle=null, refAbstract=null), Reference(id=1330127205499252878, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Ferraro PM, Ferraccioli GF, Gambaro G, et al. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial[J]. Nephrol Dial Transplant, 2009, 24(1): 156-160., articleTitle=null, refAbstract=null), Reference(id=1330127205616693391, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy[J]. J Am Soc Nephrol, 2012, 23(6): 1108-1116., articleTitle=null, refAbstract=null), Reference(id=1330127207239889040, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study[J]. J Am Soc Nephrol, 2015, 26(9): 2248-2258., articleTitle=null, refAbstract=null), Reference(id=1330127207386689681, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy[J]. N Engl J Med, 2015, 373(23): 2225-2236., articleTitle=null, refAbstract=null), Reference(id=1330127207445409938, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Lv J, Zhang H, Wong MG, et al. Effect of oral methyl-prednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial[J]. J Am Med Assco, 2017, 318(5): 432-442., articleTitle=null, refAbstract=null), Reference(id=1330127207516713107, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy[J]. J Am Soc Nephrol, 2002, 13(1): 142-148., articleTitle=null, refAbstract=null), Reference(id=1330127207575433364, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Mitsuiki K, Harada A, Okura T, et al. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide[J]. Clin Exp Nephrol, 2007, 11(4): 297-303., articleTitle=null, refAbstract=null), Reference(id=1330127207642542229, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Lv J, Yang Y, Zhang H, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study[J]. J Am Soc Nephrol, 2013, 24(12): 2118-2125., articleTitle=null, refAbstract=null), Reference(id=1330127207705456790, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=陈香美, 陈仆, 蔡广研, 等. 麦考酚酸酯治疗IgA肾病的随访对照观察[J]. 中华医学杂志, 2002, 82(12): 796-801., articleTitle=null, refAbstract=null), Reference(id=1330127207768371351, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy[J]. Kidney Int, 2005, 68(2): 802-812., articleTitle=null, refAbstract=null), Reference(id=1330127207835480216, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu X, Dewei D, Sun S, et al. Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone[J]. Int J Clin Pharmacol Ther, 2014, 52(2): 95-102., articleTitle=null, refAbstract=null), Reference(id=1330127207898394777, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study[J]. Kidney Int, 2004, 65(5): 1842-1849., articleTitle=null, refAbstract=null), Reference(id=1330127207961309338, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial[J]. Nephrol Dial Transplant, 2005, 20(10): 2139-2145., articleTitle=null, refAbstract=null), Reference(id=1330127208028418203, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy[J]. Am J Kidney Dis, 2015, 66(5): 783-791., articleTitle=null, refAbstract=null), Reference(id=1330127208087138460, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Roccatello D, Rossi D, Marletto F, et al. Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression[J]. J Nephrol, 2012, 25(2): 198-203., articleTitle=null, refAbstract=null), Reference(id=1330127208179413149, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Smerud HK, Barany P, Lindstrom K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria[J]. Nephrol Dial Transplant, 2011, 26(10): 3237-3242., articleTitle=null, refAbstract=null), Reference(id=1330127208246522014, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Fellstrom BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial[J]. Lancet, 2017, 389(10084): 2117-2127., articleTitle=null, refAbstract=null), Reference(id=1330127208326213791, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Sugiura H, Takei T, Itabashi M, et al. Effect of single-dose rituximab on primary glomerular diseases[J]. Nephron Clin Pract, 2011, 117(2): c98-c105., articleTitle=null, refAbstract=null), Reference(id=1330127208401711264, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of Rituximab in IgA nephropathy with proteinuria and renal dysfunction[J]. J Am Soc Nephrol, 2017, 28(4): 1306-1313., articleTitle=null, refAbstract=null), Reference(id=1330127208464625825, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767): 721-731., articleTitle=null, refAbstract=null), Reference(id=1330127208561094818, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy[J]. J Am Soc Nephrol, 2010, 21(10): 1783-1790., articleTitle=null, refAbstract=null), Reference(id=1330127208624009379, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Inoue T, Sugiyama H, Kitagawa M, et al. Abnormalities of glycogenes in tonsillar lymphocytes in IgA nephropathy[J]. Adv Otorhinolaryngol, 2011, 72(1): 71-74., articleTitle=null, refAbstract=null), Reference(id=1330127208758227108, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang Y, Chen J, Wang Y, et al. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy[J]. Nephrol Dial Transplant, 2011, 26(6): 1923-1931., articleTitle=null, refAbstract=null), Reference(id=1330127208829530277, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Kawamura T, Yoshimura M, Miyazaki Y, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin a nephropathy[J]. Nephrol Dial Transplant, 2014, 29(8): 1546-1553., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330127203532124278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, awardId=闽卫医政函[2017]739, language=CN, fundingSource=福建省临床重点专科建设项目(闽卫医政函[2017]739), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330127200906489955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, xref=null, ext=[AuthorCompanyExt(id=1330127200919072868, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China), AuthorCompanyExt(id=1330127200935850085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2018.02.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2018.02.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2018.02.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2018.02.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1518192000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
IgA肾病诊断和治疗进展
阮一平 , 洪富源 *
世界临床药物 | 医药专论·慢性肾脏病的诊疗专题 2018,39(2): 80-86
收起
收藏切换
世界临床药物 |医药专论·慢性肾脏病的诊疗专题 2018 , 39 (2) : 80 -86
IgA肾病诊断和治疗进展
全屏
[Author(id=1330127201028124775, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127201124593769, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, authorId=1330127201028124775, language=EN, stringName=Yi-ping RUAN, firstName=Yi-ping, middleName=null, lastName=RUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127202747789418, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, authorId=1330127201028124775, language=CN, stringName=阮一平, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001, bio={"content":"

阮一平,主治医师,主要研究方向为原发性肾小球疾病。

"}, bioImg=null, bioContent=

阮一平,主治医师,主要研究方向为原发性肾小球疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127200906489955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, xref=null, ext=[AuthorCompanyExt(id=1330127200919072868, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China), AuthorCompanyExt(id=1330127200935850085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001)])]), Author(id=1330127202852647020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330127202928144494, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, authorId=1330127202852647020, language=EN, stringName=Fu-yuan HONG, firstName=Fu-yuan, middleName=null, lastName=HONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127202991059055, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, authorId=1330127202852647020, language=CN, stringName=洪富源, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127200906489955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, xref=null, ext=[AuthorCompanyExt(id=1330127200919072868, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China), AuthorCompanyExt(id=1330127200935850085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127200214429792, companyId=1330127200906489955, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001)])])]
阮一平, 洪富源*
作者信息
  • 福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001
通讯作者:
洪富源,主任医师,硕士生导师,主要研究方向原发性肾小球疾病和肾脏病替代治疗。
作者简介:

阮一平,主治医师,主要研究方向为原发性肾小球疾病。

Progress of the diagnosis and treatment for IgA (immunoglobin A) nephropathy
Yi-ping RUAN, Fu-yuan HONG*
Affiliations
  • Department of Nephrology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China
出版时间: 2018-02-10 doi: 10.13683/j.wph.2018.02.002
文章导航
收藏切换

IgA肾病是一种常见的原发性肾小球肾炎,肾活检是诊断IgA肾病的金标准,近年来出现的一些新的诊断标志物和新型治疗药物为疾病的诊断和治疗提供了新思路。目前尚缺乏特异性免疫抑制治疗方案。本文综述IgA肾病的诊断和治疗新进展。

IgA肾病  /  诊断  /  治疗

IgA nephropathy is the most common primary glomerulonephritis. Renal biopsy remains the definitive diagnostic method of IgA nephropathy. Recently, the development of new diagnostic markers and therapeutic drugs provide some new ideas for the diagnosis and treatment of IgA nephropathy. There is still a lack of specific immunosuppressive therapy. This review describes the progress of IgA nephropathy diagnosis and its treatment.

IgA nephropathy  /  diagnosis  /  treatment
阮一平, 洪富源. IgA肾病诊断和治疗进展. 世界临床药物, 2018 , 39 (2) : 80 -86 . DOI: 10.13683/j.wph.2018.02.002
Yi-ping RUAN, Fu-yuan HONG. Progress of the diagnosis and treatment for IgA (immunoglobin A) nephropathy[J]. World Clinical Drug, 2018 , 39 (2) : 80 -86 . DOI: 10.13683/j.wph.2018.02.002
  • 福建省临床重点专科建设项目(闽卫医政函[2017]739)
参考文献 引证文献
排序方式:
[1]
Cheng J, Zhang W, Zhang X H, et al. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials[J]. Int J Clin Pract, 2009, 63(6): 880-888.
[2]
Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification[J]. Kidney Int, 2009, 76(5): 534-545.
[3]
Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments[J]. Kidney Int, 2014, 86(4): 828-836.
[4]
Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels[J]. Kidney Int, 2007, 71(11): 1148-1154.
[5]
Tam KY, Leung JC, Chan LY, et al. Macromolecular IgA1 taken from patients with familial IgA nephropathy or their asymptomatic relatives have higher reactivity to mesangial cells in vitro[J]. Kidney Int, 2009, 75(12): 1330-1339.
[6]
Kiryluk K, Moldoveanu Z, Sanders JT, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis[J]. Kidney Int, 2011, 80(1): 79-87.
[7]
Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1[J]. J Clin Invest, 2008, 118(2): 629-639.
[8]
Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity[J]. J Clin Invest, 2009, 119(6): 1668-1677.
[9]
Novak J, Tomana M, Matousovic K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells[J]. Kidney Int, 2005, 67(2): 504-513.
[10]
Stangou M, Alexopoulos E, Papagianni A, et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin a nephropathy[J]. Nephrology (Carlton), 2009, 14(6): 613-620.
[11]
Szeto CC, Li PK. MicroRNAs in IgA nephropathy[J]. Nat Rev Nephrol, 2014, 10(5): 249-256.
[12]
Nishiyama A, Konishi Y, Ohashi N, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy[J]. Nephrol Dial Transplant, 2011, 26(1): 170-177.
[13]
Zhang JJ, Jiang L, Liu G, et al. Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity[J]. Scand J Immunol, 2009, 69(5): 457-464.
[14]
Bazzi C, Rizza V, Raimondi S, et al. In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression[J]. Clin J Am Soc Nephrol, 2009, 4(5): 929-935.
[15]
Serino G, Sallustio F, Cox SN, et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy[J]. J Am Soc Nephrol, 2012, 23(5): 814-824.
[16]
Serino G, Pesce F, Sallustio F, et al. In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy[J]. Kidney Int, 2016, 89(3): 683-692.
[17]
Reid S, Cawthon PM, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy[J]. Cochrane Database Syst Rev, 2011, 16(3): CD003962.
[18]
Tang SC, Lin M, Tam S, et al. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study[J]. Nephrol Dial Transplant, 2012, 27(2): 613-618.
[19]
Szeto CC, Kwan BC, Chow KM, et al. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy-a randomized cross-over study[J]. PLoS One, 2013, 8(5): e62736.
[20]
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient[J]. Kidney Int, 2012, 82(8): 840-856.
[21]
De Caterina R, Endres S, Kristensen SD, et al. n-3 fatty acids and renal diseases[J]. Am J Kidney Dis, 1994, 24(3): 397-415.
[22]
Donadio JJ, Bergstralh EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group[J]. N Engl J Med, 1994, 331(18): 1194-1199.
[23]
Donadio JJ, Larson TS, Bergstralh EJ, et al. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy[J]. J Am Soc Nephrol, 2001, 12(4): 791-799.
[24]
Ferraro PM, Ferraccioli GF, Gambaro G, et al. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial[J]. Nephrol Dial Transplant, 2009, 24(1): 156-160.
[25]
Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy[J]. J Am Soc Nephrol, 2012, 23(6): 1108-1116.
[26]
Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study[J]. J Am Soc Nephrol, 2015, 26(9): 2248-2258.
[27]
Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy[J]. N Engl J Med, 2015, 373(23): 2225-2236.
[28]
Lv J, Zhang H, Wong MG, et al. Effect of oral methyl-prednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial[J]. J Am Med Assco, 2017, 318(5): 432-442.
[29]
Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy[J]. J Am Soc Nephrol, 2002, 13(1): 142-148.
[30]
Mitsuiki K, Harada A, Okura T, et al. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide[J]. Clin Exp Nephrol, 2007, 11(4): 297-303.
[31]
Lv J, Yang Y, Zhang H, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study[J]. J Am Soc Nephrol, 2013, 24(12): 2118-2125.
[32]
陈香美, 陈仆, 蔡广研, 等. 麦考酚酸酯治疗IgA肾病的随访对照观察[J]. 中华医学杂志, 2002, 82(12): 796-801.
[33]
Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy[J]. Kidney Int, 2005, 68(2): 802-812.
[34]
Liu X, Dewei D, Sun S, et al. Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone[J]. Int J Clin Pharmacol Ther, 2014, 52(2): 95-102.
[35]
Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study[J]. Kidney Int, 2004, 65(5): 1842-1849.
[36]
Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial[J]. Nephrol Dial Transplant, 2005, 20(10): 2139-2145.
[37]
Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy[J]. Am J Kidney Dis, 2015, 66(5): 783-791.
[38]
Roccatello D, Rossi D, Marletto F, et al. Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression[J]. J Nephrol, 2012, 25(2): 198-203.
[39]
Smerud HK, Barany P, Lindstrom K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria[J]. Nephrol Dial Transplant, 2011, 26(10): 3237-3242.
[40]
Fellstrom BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial[J]. Lancet, 2017, 389(10084): 2117-2127.
[41]
Sugiura H, Takei T, Itabashi M, et al. Effect of single-dose rituximab on primary glomerular diseases[J]. Nephron Clin Pract, 2011, 117(2): c98-c105.
[42]
Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of Rituximab in IgA nephropathy with proteinuria and renal dysfunction[J]. J Am Soc Nephrol, 2017, 28(4): 1306-1313.
[43]
Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767): 721-731.
[44]
Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy[J]. J Am Soc Nephrol, 2010, 21(10): 1783-1790.
[45]
Inoue T, Sugiyama H, Kitagawa M, et al. Abnormalities of glycogenes in tonsillar lymphocytes in IgA nephropathy[J]. Adv Otorhinolaryngol, 2011, 72(1): 71-74.
[46]
Wang Y, Chen J, Wang Y, et al. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy[J]. Nephrol Dial Transplant, 2011, 26(6): 1923-1931.
[47]
Kawamura T, Yoshimura M, Miyazaki Y, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin a nephropathy[J]. Nephrol Dial Transplant, 2014, 29(8): 1546-1553.
2018年第39卷第2期
15
5
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2018.02.002
  • 接收时间:2017-10-11
  • 首发时间:2026-11-19
  • 出版时间:2018-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2017-10-11
  • 修回日期:2017-12-07
基金
福建省临床重点专科建设项目(闽卫医政函[2017]739)
作者信息
    福建省立医院肾内科,福建省医科大学省立临床医学院,福州 350001

通讯作者:

洪富源,主任医师,硕士生导师,主要研究方向原发性肾小球疾病和肾脏病替代治疗。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2018.02.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏